Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride -

ABD - İngilizce - NLM (National Library of Medicine)

zoetis inc. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 2 mg - anipryl tablets are indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (cds) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (pdh). anipryl is contraindicated in patients with known hypersensitivity to this drug.  in humans, selegiline is contraindicated for use with meperidine and this contraindication is often extended to other opioids.

ABD - İngilizce - NLM (National Library of Medicine)

mylan specialty l.p. - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 5 mg

Kanada - İngilizce - Health Canada

mylan pharmaceuticals ulc - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Kanada - İngilizce - Health Canada

teva canada limited - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Kanada - İngilizce - Health Canada

aa pharma inc - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - selegiline hydrochloride -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - selegiline hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: citric acid monohydrate; purified talc; maize starch; magnesium stearate; povidone; lactose monohydrate - may be of benefit as an adjunct in the management of late stage parkinson's disease in patients being treated with levodopa with/without a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response of therapy. indications as at 1 december 1999: treatment of patients with parkinson's disease. it can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor).

ABD - İngilizce - NLM (National Library of Medicine)

american health packaging - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone hydrochloride 150 mg - trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (mdd) in adults. trazodone hydrochloride tablets are contraindicated in: - patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (maois), including maois such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see warnings and precautions ( 5.2), drug interactions ( 7.1)]. teratogenic effects pregnancy category c trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in the rat when given at dose levels approximately 6 to 9 times the maximum recommended human dose (mrhd) of 400 mg/day on mg/m 2 in adolescents. there was also an increase in congenital anomalies in the rabbit at approximately 6 to 17 times the mrhd on mg/m 2 basis in adolescents . there are no adequate and well-controlled studies in pregnant women. trazodone hydrochloride should be used during pregnancy only if the po